Akari Therapeutics

$2.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (+0.34%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell AKTX and other stocks, options, and ETFs commission-free!

About AKTX

Akari Therapeutics plc ADR (0.01 USD), also called Akari Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom. The listed name for AKTX is Akari Therapeutics plc ADR (0.01 USD).

CEO

Clive Stuart Richardson

Employees

Headquarters

London, London & South East

Founded

2004

Market Cap

110.10M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

612.35K

High Today

$3.08

Low Today

$2.67

Open Price

$2.89

Volume

272.52K

52 Week High

$3.76

52 Week Low

$0.87

Collections

AKTX Earnings

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 31, Pre-Market